KOSDAQBiotech & Pharma0156T0

HL Genomics

₩6,000▼ 0.66%2026-11-18 close
Market Cap
₩46.7B
Turnover
₩100M
Volume
30K
Shares out.
7.8M
PER
—
PBR
0.4×
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

High-margin API maker, parent reliance and capacity

HL Genomics keeps a solid 30%-plus operating margin and a 19-year profit record, but cumulative third-quarter 2026 revenue and profit both declined as single-plant capacity and parent dependence come into focus.

  1. 1

    Cumulative third-quarter 2026 revenue of KRW 7.02 billion fell 11.2% year on year, operating profit of KRW 2.11 billion fell 25.2%, and net income of KRW 1.99 billion fell 20.7%.

  2. 2

    Operating margin ran at 30.9% in 2023, 31.8% in 2024 and 32.3% in 2025, and the company reports 19 consecutive years of profitability.

  3. 3

    The first plant runs at saturation levels, which caps top-line growth, and the Yongin second plant is slated to begin full production and sales from 2029.

  4. 4

    Sales to the parent company reached 59.19% in the first quarter of 2026, leaving the demonstration of an independent customer base as an open task.

  5. 5

    Lock-up commitments covered only 1.90% of subscribed shares, creating supply pressure after listing, and the share price has traded below the KRW 21,500 offering price.

02

Business structure

HL Genomics is a manufacturer of active pharmaceutical ingredients (APIs) founded in 2000, and it is the first affiliate of its parent group to go public.

Using high-purity crystallization and impurity control technology, it produces APIs for chronic disease therapies across cardiovascular, respiratory, musculoskeletal and neurological areas.

By 2025, cardiovascular products made up 45.2% of sales, followed by allergy (respiratory) at 27.6%, musculoskeletal at 7.9% and neurology at 7.3%. Concentration in recurring-prescription categories gives the portfolio relatively steady demand, according to some analysts.

All production runs at a single plant in Yongin, built in 2007, and utilization was 106.1% in 2023, 124.0% in 2024 and 117.8% in 2025. Sales to the parent company accounted for 59.19% in the first quarter of 2026, while exports were roughly 4% of the total.

On cost efficiency, the SG&A ratio was 11.1% in 2025, compared with 30.5% and 16.3% at two comparison companies. The company plans to extend into CMO and CDMO services and vaccine microneedle contract manufacturing after its second plant comes online.

03

Recent trends

Cumulative third-quarter 2026 results on a consolidated basis show revenue of KRW 7.02 billion, operating profit of KRW 2.11 billion and net income of KRW 1.99 billion, down 11.2%, 25.2% and 20.7% year on year respectively.

The simultaneous decline in sales and profit suggests that production capacity is capping top-line growth. On an annual basis, revenue rose from KRW 24.8 billion in 2023 to KRW 28.2 billion in 2024 and KRW 28.9 billion in 2025, while operating profit moved from KRW 7.7 billion to KRW 9.0 billion and KRW 9.3 billion.

Operating margin stood at 30.9% in 2023, 31.8% in 2024 and 32.3% in 2025, staying above 30% for three straight years. Revenue growth, however, slowed from 13.52% in 2024 to 2.52% in 2025 and 2.35% in the first quarter of 2026, according to a Green Economy report.

The same report said gross margin improved from 37.98% in 2023 to 45.62% in the first quarter of 2026. The IPO was priced at the top of the indicative range at KRW 21,500, with institutional demand at 714.5 to 1. Press reports indicate the stock has traded below the offering price since listing.

As of 15:03 KST on November 14, 2026, the share price was KRW 6,620, down 0.45% from the prior close, with a market capitalization of KRW 51.5 billion.

04

Outlook

The key variables for future growth are the timing of the Yongin second plant build-out and the pace of its investment. The company set targets of construction start in the third quarter of 2026, building completion by the end of 2027 and full setup by the end of 2028, with production and sales fully starting in 2029.

The planned investment is about KRW 76.5 billion, and the CEO estimated the total at KRW 75.9 billion, with KRW 12.1 billion already spent. On liquidity, the company cited cash and deposits of about KRW 38 billion and annual operating cash flow in the KRW 6 billion range.

Before the second plant opens, the company plans to maintain output through process improvements at the first plant and productivity verification across seven products.

After the second plant starts, depreciation could rise from roughly KRW 600 million a year to as much as KRW 3.59 billion, which may temporarily lower reported operating margin. The company expects output capacity per product to rise 1.5 to 2 times and manufacturing costs to improve by 10% to 30%.

It also set a goal of reducing parent-company sales to the 40% range over time. The revenue contribution from CMO, CDMO and vaccine microneedle manufacturing will become visible from 2029 onward as the second plant operates.

05

Bull factors

19 years of profit and 30%-plus operating margin

Consolidated operating margin was 30.9% in 2023, 31.8% in 2024 and 32.3% in 2025, staying above 30% for three straight years, with a three-year average of 31.7%. The company reports 19 consecutive years of operating and net profit. The 2025 SG&A ratio of 11.1% was below the 30.5% and 16.3% of two comparison companies.

At the end of 2025, equity stood at KRW 83.6 billion, total liabilities at KRW 5.5 billion and the debt ratio at 6.6%.

Second plant targets 1.5 to 2 times capacity

Utilization at the first plant was 106.1% in 2023, 124.0% in 2024 and 117.8% in 2025, leaving little room for additional output. The company expects the Yongin second plant to lift output per product by 1.5 to 2 times and cut manufacturing costs by 10% to 30%.

The new facility will include one large line and two small lines, with EU GMP standards and automation. Whether the expansion converts into orders and sales will become clear through operating results from 2029.

CMO, CDMO and vaccine microneedle options

The company plans to use the small lines in the second plant for partner-type CMO and CDMO services serving domestic and overseas drugmakers and startups.

A 2023 strategic partnership gave it exclusive global production rights for vaccine microneedles, with the manufacturing site planned within the second plant grounds. HL267, a macular degeneration therapy being co-developed with the parent company, was cited as a key example. Revenue scale from these businesses has not yet been disclosed, so their assessment will depend on progress.

06

Bear factors

Reliance on parent company sales

Sales to the parent company accounted for 59.19% in the first quarter of 2026, more than half of the total. The top four customers made up 87.23% of revenue, and analysts noted that the parent accounted for 54.52% of that group.

Before listing, the company submitted a commitment barring the controlling shareholder from direct or indirect management involvement after the IPO. The company says it is building an independent sales base through external customers, but those gains have not yet shown up in reported figures.

Growth stall until the second plant ramps

Cumulative third-quarter 2026 revenue of KRW 7.02 billion fell 11.2% year on year. Revenue growth slowed from 13.52% in 2024 to 2.52% in 2025 and 2.35% in the first quarter of 2026. Analysts attribute the slowdown to a saturated first plant that cannot add output. Meaningful growth drivers remain limited until second-plant sales begin in 2029.

Post-listing supply pressure and weak share price

The lock-up commitment rate was only 1.90% of subscribed shares, so most offering shares could be sold from the first trading day. Tradable shares immediately after listing were limited to roughly 33% of total issued shares.

Reports say the stock has stayed weak since listing and trades well below the KRW 21,500 offering price. The controlling shareholder's stake is locked up for two years and six months, but holdings could be released in stages once that period ends.

07

Risk factors

Policy risk

Revisions to drug price cuts could pressure drugmakers' profitability and, in turn, push API suppliers to lower their prices. The company said APIs account for only 15% to 25% of finished-drug costs, so price cuts would not apply uniformly and the financial impact should be limited.

Because sales are concentrated among a few customers, policy changes could still reach the company indirectly through those customers' margins.

Capex and depreciation risk

The second plant investment is estimated at about KRW 76.5 billion, of which KRW 12.1 billion had been spent by the time of the IPO materials. After operations begin, depreciation could rise from about KRW 600 million a year to as much as KRW 3.59 billion.

Any construction delay would also push back the start of meaningful sales beyond 2029, while the company cites cash deposits of about KRW 38 billion and annual operating cash flow as funding sources.

Governance risk

After listing, the parent company and related parties will continue to hold about 66.27% of the shares. Related-party transactions and intra-group fund flows are cited as the central points for judging governance independence.

The company committed that the largest shareholder will waive dividends for five years and that proceeds from secondary sales will be used only for facility investment. Whether independent directors and internal control systems operate effectively remains a point to be verified.

08

Overall view

HL Genomics combines a 30%-plus operating margin, 19 consecutive years of profitability and a debt ratio of 6.6%. However, cumulative third-quarter 2026 revenue and profit both declined, and revenue growth has stayed in the low single digits since 2025.

On the production side, the saturated first plant caps top-line growth, and meaningful growth drivers remain limited until the second plant ramps up in 2029.

Reliance on parent-company sales, related-party transactions and a tightly limited tradable share base remain open challenges for independence and supply dynamics. Depreciation will rise after the second plant starts, which could temporarily lower reported operating margin.

Whether the second plant, CMO and CDMO services and vaccine microneedle manufacturing translate into reported earnings is the key point that will shape the medium-term trajectory.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 10 more articles and sources
  1. hankyung.com
  2. mt.co.kr
  3. medicaltimes.com
  4. newspim.com
  5. greened.kr
  6. smarttoday.co.kr
  7. yakup.com
  8. m.news.nate.com
  9. medipana.com
  10. thevc.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis